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Loss of pyruvate kinase M2 limits growth and
triggers innate immune signaling in endothelial
cells
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Despite their inherent proximity to circulating oxygen and nutrients, endothelial cells (ECs)
oxidize only a minor fraction of glucose in mitochondria, a metabolic specialization that is
poorly understood. Here we show that the glycolytic enzyme pyruvate kinase M2 (PKM2)
limits glucose oxidation, and maintains the growth and epigenetic state of ECs. We find that
loss of PKM2 alters mitochondrial substrate utilization and impairs EC proliferation and
migration in vivo. Mechanistically, we show that the NF-κB transcription factor RELB is
responsive to PKM2 loss, limiting EC growth through the regulation of P53. Furthermore, S-
adenosylmethionine synthesis is impaired in the absence of PKM2, resulting in DNA hypo-
methylation, de-repression of endogenous retroviral elements (ERVs) and activation of
antiviral innate immune signalling. This work reveals the metabolic and functional con-
sequences of glucose oxidation in the endothelium, highlights the importance of PKM2 for
endothelial growth and links metabolic dysfunction with autoimmune activation in ECs.
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The vertebrate vascular system comprises a vast and evo-lutionarily conserved network that supports tissue growthand homoeostasis1. Recent work has highlighted the high
glycolytic rate of the endothelial cells (ECs) that line this net-
work2, which under physiological conditions metabolize almost
90% of cellular glucose anaerobically to produce lactate3. The
ability to generate ATP in this manner permits EC migration into
non-perfused tissues and allows the expansion of vascular net-
works during organ growth2,4,5. Given these distinct metabolic
traits, endothelial mitochondria have been considered to function
largely as signalling organelles6,7, and the consequences of
enhanced glucose oxidation in ECs are not well described. Recent
work has shown that mitochondria play fundamental roles in EC
growth and homoeostasis; β-oxidation of fatty acids is required
for dNTP synthesis8, while glutamine metabolism is an essential
source of TCA cycle intermediates that are necessary to support
macromolecule biosynthesis in ECs3,9.
To gain insight into the functional and metabolic consequences
of glucose oxidation in ECs, we analysed the function of the
pyruvate kinase (PK) isozyme PKM2, which has been associated
with aerobic glycolysis and growth in cancer cells10,11, and the
maintenance of mitochondrial function in diabetic nephro-
pathy12. Pyruvate kinase catalyses the final step in glycolysis,
generating pyruvate and ATP from phosphoenolpyruvate and
ADP13. In higher vertebrates, two genes (PKLR and PKM) encode
four PK isozymes that vary in their expression patterns and
activity14. Alternative splicing of the PKM gene to include exon 9
or 10 generates the PKM1 and PKM2 isozymes, respectively15.
While PKM1 exhibits constitutively high PK activity and
its expression is associated with a decrease in cell growth, the
catalytic activity of PKM2 is modulated allosterically by
critical metabolic intermediates16–18 and post-translationally in
response to growth factor signalling and reactive oxygen species
(ROS)10,19, providing a focal point for the integration of cellular
signalling and redox status with glycolytic flux. Here we show that
loss of PKM2 in ECs results in TCA cycle dysfunction, cell cycle
arrest and the induction of viral mimicry by endogenous retro-
viral transcripts.
Results
Loss of endothelial PKM2 alters mitochondrial metabolism.
The PKM gene is abundantly expressed in ECs (Supplementary
Figure 1a), and RT-qPCR (Fig. 1a) and western blot (Fig. 1b)
analyses show that PKM2 is the predominant isoform. To deter-
mine the function of endothelial PKM2, we first assessed the
efficacy of validated siRNA duplexes targeting specifically PKM2
(PKM2KD) or both PKM splice isoforms (PKMKD) in primary
human umbilical vein ECs (HUVECs) (Supplementary Figure 1)20.
Functionally, while neither PKM2KD nor PKMKD significantly
changed cellular energy charge (Fig. 1c), incorporation of [U-
13C6]-glucose-derived carbon into m+3 lactate (Fig. 1d) and
extracellular acidification rate (ECAR) (Supplementary Figure 1g)
were significantly reduced in both conditions. The reduction in
labelled lactate was coupled to an increase in [U-13C6]-glucose
labelling of citrate (Fig. 1e) and oxygen consumption rate (OCR)
(Fig. 1f) in PKM2KD ECs but not in PKMKD ECs, indicating that
PKM isoform expression is a critical determinant of the fate of
glucose-derived carbon in ECs. Intriguingly, analysis of steady-state
levels of TCA cycle intermediates revealed a decrease in total α-
ketoglutarate (α-KG), fumarate and malate in PKM2KD and
PKMKD ECs, while aspartate levels were significantly increased
only in PKM2KD ECs (Supplementary Figure 1h). Furthermore,
[U-13C6]-glucose labelling of α-KG (Fig. 1g) was significantly
reduced in PKM2KD and PKMKD ECs, while aspartate labelling
was increased only in PKM2KD ECs (Fig. 1h), indicating that
significant changes to TCA cycle metabolism occur in the absence
of PKM2. Glycolysis is not the sole carbon source for the TCA
cycle, which is also fuelled by branched chain amino acid (BCAA)
oxidation, pyruvate anaplerosis, fatty acid oxidation (FAO) and
glutamine metabolism3,9. We found that PKM2KD, but not
PKMKD, led to a reduction in the ratio of keto-leucine to isoleucine
(Fig. 1i) and [U-13C6]-glucose labelling of m+3 alanine (Fig. 1j),
while an accumulation of long-chain acylcarnitines (Fig. 1k), and
reduced m+3 malate (Supplementary Figure 1i) were observed in
both PKM2KD and PKMKD ECs. These data indicate that BCAA
oxidation, pyruvate anaplerosis and FAO are impaired in PKM2KD
ECs. Mitochondria are an important source of ROS in endothelial
cells, where at low levels ROS perform critical signalling func-
tions21. We found that while the global ratio of GSSG/GSH
(Supplementary Figure 1j) and cellular ROS levels (Supplementary
Figure 1k) were not changed in PKM2KD ECs, there was an
increase in mitochondrial superoxide levels (Fig. 1l). Furthermore,
we did not observe changes in mitochondrial DNA content
(Supplementary Figure 1l). Collectively, these data show that loss of
PKM2 alters mitochondrial metabolism and is associated with the
disruption of multiple pathways that fuel TCA cycle metabolism
and cell growth.
Loss of PKM2 impairs angiogenic sprouting. To understand the
functional importance of PKM2 for angiogenic sprouting, we
assessed EC migration and proliferation in primary cells, zebra-
fish and mice. In HUVECs, PKM2KD led to a decrease in the
number of 5-ethynyl-2′-deoxyuridine positive (EdU+) (Fig. 2a)
and phospho-Histone H3 positive (pHH3+) (Supplementary
Figure 2a) ECs, and cell cycle arrest in G0/G1 at 48 h after siRNA
transfection (Supplementary Figure 2b), resulting in a significant
reduction in relative EC number (Fig. 2b). We also observed a
decrease in EC proliferation using ML265, a small-molecule
activator of PKM2 tetramerization that mimics the effects of
PKM2 loss of function, providing further evidence that modula-
tion of PKM2 activity can inhibit EC proliferation (Supplemen-
tary Figure 2c). Furthermore, PKM2KD significantly impaired
wound closure in an in vitro scratch wound assay, indicating that
PKM2 may also play an important role in EC migration (Fig. 2c).
To assess the in vivo relevance of these findings, we generated
mutants in the zebrafish orthologues, pkma and pkmb (Supple-
mentary Figure 2d–g). The zebrafish pkma gene displays a similar
genomic organization as its mammalian orthologues (Supple-
mentary Figure 2d), and is alternatively spliced into exon 9 or 10
to give rise to mRNAs that we have designated as pkma1 and
pkma2. In contrast, in zebrafish and other teleosts, the pkmb gene
contains 11 exons and is not subject to alternative splicing
(Supplementary Figure 2d). Clustering analysis based on a 56
amino acid sequence with homology to the amino acids encoded
by exon 9 or 10 of the human PKM gene (Supplementary Figure
2e), indicates that pkmb is an orthologue of mammalian PKM2,
not PKM1. Confocal analyses of wild-type, maternal zygotic
pkma2 (pkma2mz) and pkma2mz/pkmb−/− mutant embryos
revealed defects in the formation of the intersegmental vessels
(ISVs) (Fig. 2d). Live imaging demonstrated impaired prolifera-
tion and migration of ECs in the ISVs of pkma2mz/pkmb−/−
mutants (Supplementary Movie 1). Quantification of incomplete
ISVs at 48 h post fertilization (hpf) reveals a significant increase
in the number of ISVs that fail to make connections with their
neighbours in pkma2mz/pkmb−/− mutants (Fig. 2e), indicating
that Pkm2 regulates blood vessel growth in vivo.
To interrogate the endothelial cell autonomous requirement for
PKM2 during vessel growth, we conditionally deleted exon 10 of
the Pkm gene (Supplementary Figure 3a, b) in endothelial cells of
mice and analysed angiogenesis in the postnatal retina. To this
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end, we intercrossed Pkm2flox mice with Pdgfb-CreERT2 mice
(referred to hereafter as Pkm2iEC-KO) and induced recombination
by 4-hydroxy-tamoxifen (4-OHT) injection from postnatal day
(P) 1–3. Staining of retinas for PECAM (marking EC mem-
branes) and ERG (marking EC nuclei) at P7 revealed reduced
outgrowth of a hypo-cellular vascular plexus in Pkm2iEC-KO mice
(Fig. 3a, b). To determine the cause of this phenotype, we
analysed the morphology and growth of vessels at the angiogenic
front in PECAM, ERG and EdU-stained retinas (Fig. 3c).
Quantification revealed a significant reduction in EC number,
proliferation, vessel area and branching in Pkm2iEC-KO mice
(Fig. 3d). In contrast to the vascular defects at the angiogenic
front, the central plexus of the retina was less affected by PKM2
inactivation using the Pdgfb-CreERT2 (Supplementary Figure 3c).
While endothelial cellularity was significantly reduced, vessel area
and branch point density were similar to controls (Supplementary
Figure 3e). These findings are consistent with the enrichment of
PKM2 in angiogenic ECs22 and suggest that PKM2 signalling is
particularly important for vessel sprouting at the growing
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Fig. 1 Loss of endothelial PKM2 leads to mitochondrial dysfunction. a RT-qPCR analysis of PKM mRNA expression showing that PKM2 is more abundantly
expressed in HUVECs (n= 3). b Western blot analysis of PKM1 and PKM2 expression in HUVECs, HEK293 and mouse skeletal muscle. c Relative energy
charge ([ATP]+ 1/2[ADP]/[ATP]+ [ADP]+ [AMP]) in control, PKM2KD and PKMKD ECs (n= 3). Incorporation of [U-13C6]-glucose into m+3 lactate
(d) and m+2 citrate (e) in control, PKM2KD and PKMKD ECs (n= 3). f Oxygen consumption rate (OCR) in control, PKM2KD and PKMKD ECs under basal
conditions and in response to oligomycin, fluoro-carbonyl cyanide phenyl-hydrazone (FCCP) and antimycin A/rotenone (n= 6, data represent mean ± s.
d.). g Incorporation of [U-13C6]-glucose into m+2 α-ketoglutarate in control, PKM2KD and PKMKD ECs (n= 3). h Incorporation of [U-13C6]-glucose into m
+2 aspartate in control, PKM2KD and PKMKD ECs (n= 3). i Ratio of keto-leucine/isoleucine in control, PKM2KD and PKMKD ECs. j Incorporation of [U-
13C6]-glucose into m+3 alanine in control, PKM2KD and PKMKD ECs (n= 3). k Relative levels of different acylcarnitine species in control, PKM2KD and
PKMKD ECs (n= 3). l Normalized MitoSOX fluorescence intensity in control, PKM2KD and PKMKD ECs. a, c–l Data represent means ± s.d., m+n represents
the mass isotopomers for individual metabolites (***P < 0.001, **P < 0.01, *P < 0.05 by one-way analysis of variance (ANOVA) followed by Tukey’s HSD
test)
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Fig. 2 Loss of PKM2 leads to angiogenic sprouting defects. a EdU-positive cell numbers in control, PKM2KD and PKMKD ECs (n= 11). b Relative cell
numbers at the indicated time points in control, PKM2KD and PKMKD ECs (n= 6). c Scratch wound assay in control and PKM2KD ECs (n= 8).
d Representative confocal projections of 48 hpf Tg(kdrl:EGFP) pkma2+/+ pkmb+/+ and pkma2MZ pkmb−/− zebrafish embryos (scale bar= 50 μm).
e Percentage of intersegmental vessels (ISVs) that have failed to connect with neighbouring ISVs in 48 hpf zebrafish embryos (n= 8). Data in a–c and

































































































































Fig. 3 Acute deletion of Pkm2 in mouse endothelial cells leads to angiogenic sprouting defects. a Representative confocal projections of PECAM, ERG and
EdU immunostained retinas from control and Pkm2iEC-KO mice (A, Artery; V, Vein). b Radial outgrowth in control and Pkm2iEC-KO mice (n= 6). c
Representative confocal projections of angiogenic front vessels in PECAM, ERG and EdU-stained retinas from control and Pkm2iEC-KO mice. d ERG+ ECs,
EdU+ ECs, EC area per field and branch point density at the angiogenic front of control and Pkm2iEC-KO mice (n= 6). All analyses in the mouse retina were
performed on postnatal day 7. Data in b and d represent means ± s.e.m. (**P < 0.01, *P < 0.05 by two-tailed Student's t test). Scale bars in a and c=
200 μm
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regression, we quantified the number of empty collagen IV+
sleeves and observed no significant difference between control
and Pkm2iEC-KO mice (Supplementary Figure 3d, e). Taken
together, these data suggest that PKM2 is a crucial regulator of
endothelial migration and proliferation, whose inactivation
compromises vascular expansion.
Coordinated metabolic and protein changes following PKM2
loss. To gain further insight into the global metabolic changes
associated with loss of endothelial PKM2, we performed pathway
analyses of steady-state metabolites and identified pathways
linked to mitochondrial metabolism23,24, including TCA cycle,
pyrimidine synthesis and cysteine and methionine metabolism
(Fig. 4a, specific metabolites highlighted in Fig. 4b). Deletion of
PKM2 in primary mouse embryonic fibroblasts (MEFs) leads to
impaired pyrimidine synthesis that does not correlate with gene
expression changes25. To determine if loss of PKM2 is associated
with gene expression changes in ECs, we performed a proteomics
analysis that revealed changes to the expression of a number of
key enzymes in the pyrimidine synthesis, and serine, glycine and
one-carbon metabolism (SGOC) pathways (Fig. 4c and Supple-
mentary Figure 4a). These data indicate that the metabolic
changes observed in PKM2KD ECs (Fig. 4a, b) correlate with
protein-level changes in the key enzymes controlling these
pathways, leading us to hypothesize that there may be a coordi-
nated transcriptional response to the loss of PKM2 in ECs.
RELB-P53 suppresses endothelial growth in the absence of
PKM2. Further analyses revealed that components of the NF-κB
and TP53 transcription factor pathways, which have previously
been linked with the regulation of metabolism26–29, are upregu-
lated in PKM2KD ECs (Supplementary Figure 5a, b). We thus set
out to test if these pathways regulate EC growth in the absence of
PKM2. Co-transfection of siRNA duplexes targeting PKM2 and
REL, RELA or RELB, revealed that silencing RELB significantly
rescued the number of EdU+ (Fig. 5a and Supplementary Figure
5c) and pHH3+ (Fig. 5a) ECs, indicating that RELB mediates the
cell cycle arrest observed in the absence of PKM2. Western blot
analysis of control, RELBKD, PKM2KD and PKM2KD/RELBKD
ECs revealed that RELB expression was increased in the absence
of PKM2 and acts to induce the expression of P53 and its
downstream target P21 (Fig. 5b).
Given the established role of the P53–P21 pathway in the
regulation of cell cycle progression30, we hypothesized that RELB-
mediated induction of P53–P21 might be the cause of the cell
cycle arrest observed in PKM2KD ECs. Quantification of EdU and
phospho-Histone H3 (Fig. 5c) positive ECs, and total cell
numbers (Supplementary Figure 5d) revealed a significant rescue
of the cell cycle arrest observed in PKM2KD ECs following
P53 silencing. Furthermore, western blot analysis showed that the
increase in P53 and its transcriptional target P21 in PKM2KD ECs
was abolished by co-transfecting siRNA duplexes targeting P53,
while RELB expression was unchanged (Fig. 5d). These data show
that RELB acts upstream of P53–P21 to induce cell cycle arrest in
the absence of PKM2. In addition to its well-documented tumour
suppressor functions30, there is an increasing appreciation of the
importance of P53 in the regulation of metabolism in response to
various types of cellular stress26. In tumour cells deprived of
exogenous serine, P53 promotes glutathione synthesis at the
expense of nucleotides to promote cell survival31. To identify
potential transcriptional and metabolic changes controlled by
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Fig. 4 Loss of PKM2 leads to coordinated metabolic and protein expression changes. a Analysis of steady-state metabolite levels in control vs PKM2KD ECs
identifies the TCA cycle, pyrimidine metabolism and cysteine and methionine metabolism as significantly regulated pathways. b Metabolomics profile of
control vs PKM2KD ECs (log2(fold change) vs −log2(p value), two-tailed Student's t test, n= 3). c Heat map of protein expression for key enzymes in the
pyrimidine synthesis and serine, glycine, one-carbon metabolic networks in control vs PKM2KD ECs
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Fig. 5 RELB-P53 suppresses endothelial growth in the absence of PKM2. a EdU and phospho-Histone H3 positive cell numbers in control, RELBKD, PKM2KD
and PKM2KD/RELBKD ECs (n= 6). bWestern blot analysis of RELB, P53, P21 and PKM2 expression in control, RELBKD, PKM2KD and PKM2KD/RELBKD ECs.
c EdU and phospho-Histone H3 positive cell numbers in control, P53KD, PKM2KD and PKM2KD/P53KD ECs (n= 12). d Western blot analysis of RELB, P53,
P21 and PKM2 expression in control, P53KD, PKM2KD and PKM2KD/P53KD ECs. e mRNA expression levels of key enzymes for pyrimidine synthesis in
control, P53KD, PKM2KD and PKM2KD/P53KD ECs (RNA-seq analysis, n= 3). f Relative N-carbamoyl aspartate levels, UTP levels, incorporation of [U-
13C6]-glucose into m+3 and m+5 UTP, and relative dTTP levels in control, P53KD, PKM2KD and PKM2KD/P53KD ECs (n= 3). a, c Data represent means ±
s.e.m., e, f data represent means ± s.d., m+n represents the mass isotopomers for individual metabolites (***P < 0.001, **P < 0.01, *P < 0.05 by one-way
analysis of variance (ANOVA) followed by Tukey’s HSD test)
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P53, we performed RNA-seq and metabolomics analyses in
control, P53KD, PKM2KD and PKM2KD/P53KD ECs. Analysis of
the transcriptional response (Supplementary Figure 5e) revealed
that P53 regulates the expression of key enzymes in the
pyrimidine synthesis pathway (Fig. 5e). Volcano plots displaying
metabolite profiles show that the relative levels of a number of
metabolites in the pyrimidine synthesis pathway are reduced
following PKM2KD (Supplementary Figure 5f), and that silencing
of P53 leads to a relative normalization of the levels of these
metabolites (Supplementary Figure 5g). Comprehensive analysis
of nucleotide levels revealed that PKM2KD reduced the relative
levels of N-carbamoyl aspartate, UTP and dTTP, and impaired
incorporation of glucose-derived carbon into UTP, while
silencing of P53 increased the levels of these metabolites (Fig. 5f).
Collectively, these data indicate that a P53-dependent transcrip-
tional programme controls the reduction in pyrimidine nucleo-
tide levels in ECs lacking PKM2.
Loss of PKM2 impairs methylation capacity and DNA
methylation. In addition to changes in the pyrimidine synthesis
pathway, loss of PKM2 also led to significant changes in the
steady-state levels of the one-carbon metabolite s-
adenosylmethionine (SAM) (Fig. 4b), which were coupled to
reduced expression of enzymes in the SGOC network (Fig. 4c). As
the primary cellular methyl group donor, the abundance of SAM
determines the methylation status of a broad range of substrates,
including DNA and histones32. SAM is an intermediate meta-
bolite in a wider metabolic network that encompasses the folate
and methionine cycles, termed one-carbon metabolism24, and is
synthesized from ATP and methionine, by methionine adeno-
syltransferases (MAT). MAT1A expression is restricted to the
liver, while MAT2A and MAT2B are expressed in non-hepatic
tissues and their expression levels have been shown to positively
correlate with DNA methylation33. Western blot analysis of
control, P53KD, PKM2KD and PKM2KD/P53KD ECs revealed a
P53-independent reduction in the expression of MAT2A in the
absence of PKM2 (Fig. 6a). Metabolomic analyses of control,
P53KD, PKM2KD and PKM2KD/P53KD ECs showed a significant
reduction in the steady-state levels of SAM (Fig. 6b), with no
concomitant decrease in S-adenosylhomocysteine (SAH) in
PKM2KD and PKM2KD/P53KD ECs (Fig. 6b), leading to a P53-
independent drop in the ratio of SAM:SAH (Fig. 6b). These
changes were associated with a reduction in the SAM-derived
metabolite S-methyl-5-thioadenosine (5MTA) in PKM2KD and
PKM2KD/P53KD ECs, with no change in methionine levels or
GSH/GSSG ratio (Supplementary Figure 6a). Altogether, these
data indicate that loss of PKM2 leads to reduced levels of SAM, in
a manner that is independent of cell cycle arrest or regulation by
P53. A reduction in the SAM:SAH ratio has been linked to a
decrease in cellular methylation capacity34, and as a consequence,
we identified a significant reduction in global DNA methylation,
as assessed by measuring the levels of methylated cytosine in
control and PKM2KD ECs (Fig. 6c).
Loss of PKM2 leads to endogenous retrovirus expression.
Methylation of DNA controls a number of biological processes that
include promoter inactivation, X-chromosome silencing and the
silencing of transposable elements35. Retrotransposons make up
close to 45% of the human genome36 and consist of two classes,
long terminal repeat (LTR) and non-LTR transposons37. De-
repression of these elements is associated with activation of the
endogenous antiviral defence pathway37. In response to an increase
of cytosolic viral RNA, a signalling cascade is triggered that begins
with recognition by cytosolic sensors, activation of interferon
regulatory factor (IRF)-NF-κB signalling and subsequent induction
of interferon-stimulated gene (ISG) expression38. Intriguingly,
global knockout of Pkm2 in mouse was recently shown to increase
systemic inflammation14, and Pkm2−/− MEFs display increased
expression of the ISGs Ifi44 and Ifih125, leading us to hypothesize
that loss of PKM2 may lead to the activation of innate immune
signalling as a consequence of reduced DNA methylation. Analysis
of our proteomics data set revealed changes in the expression of
genes associated with antiviral defence (Fig. 6d and Supplementary
Figure 6b). Furthermore, mRNA levels of a number of ISGs were
increased in PKM2KD ECs (Supplementary Figure 6c), and analysis
of published microarray data25 revealed that ISGs are induced in
Pkm2−/− MEFs (Supplementary Figure 6d), indicating that loss of
PKM2 can lead to the activation of an innate immune response in
multiple cell types and species. DNA methyltransferase (DNMT)
inhibition was recently shown to permit the expression of endo-
genous retroviral (ERV) elements, leading to the formation of
cytosolic dsRNA and activation of innate antiviral signalling39,40.
IFIH1 (MDA5) encodes a cytosolic pattern recognition receptor
that recognizes double-stranded RNA (dsRNA)41, and its expres-
sion is upregulated in both PKM2 loss-of-function ECs (Supple-
mentary Figure 6c) and MEFs (Supplementary Figure 6d). We
therefore investigated if loss of PKM2 might lead to the accumu-
lation of dsRNAs in ECs using the J2 antibody, and found a sig-
nificant increase in dsRNA levels in PKM2KD ECs (Fig. 6e, f). In
addition, RT-qPCR analyses of control and PKM2KD ECs revealed
an increase in the expression of a subclass of ERVs (Fig. 6g), which
are induced in response to DNMT inhibition39. To understand if
increased ERV expression in PKM2KD ECs was linked to changes
in DNA methylation, we performed site-specific restriction diges-
tion of PCR-amplified bisulfite-converted DNA at the MLT1B and
MER4D loci. These analyses revealed a mild reduction in DNA
methylation at the MLT1B and MER4D loci in PKM2KD ECs
(Fig. 6h), the extent of which was likely limited by the cell cycle
arrest observed following loss of PKM2. Histone H3 lysine 9 tri-
methylation (H3K9me3), which has been shown to contribute to
ERV repression in embryonic stem cells42, was not changed in
PKM2KD ECs (Supplementary Figure 7a). Collectively, our data
indicate that loss of PKM2 leads to reduced DNA methylation,
which triggers viral mimicry induced by expression of endogenous
retroviral transcripts.
ERV expression levels are limited by RELB. P53 has been shown
to limit the expression of retrotransposons in MEFs treated with
DNMT inhibitors43, and the NF-κB transcription factor family is
known to induce the expression of ISGs, forming a critical
component of the innate immune response to viral infection44.
Given the increased expression of both P53 and RELB in the
absence of PKM2, we hypothesized that these transcription fac-
tors may regulate ISG and/or ERV expression in ECs. Loss of P53
did not significantly alter ISG expression (Supplementary Figure
7b), ERV expression (Supplementary Figure 7b) or DNA
methylation (Supplementary Figure 7c) in PKM2KD ECs. In
contrast, RELB silencing led to a dramatic increase in ERV and
ISG mRNA levels in both RELBKD and PKM2KD/RELBKD ECs
(Fig. 6i). Furthermore, analysis of previously published micro-
array data from Relb−/− mouse bone-marrow-derived dendritic
cells revealed increased expression of numerous ISGs (Supple-
mentary Figure 7d)45, indicating that RELB limits innate immune
activation in multiple cell types. RELB is known to suppress
transcription through the directed recruitment of DNA methyl-
transferases and chromatin remodelling factors46, leading us to
hypothesize that RELB may limit ERV expression by regulating
local chromatin composition. Analysis of theMLT1B andMER4D
loci showed that RELBKD did not significantly alter DNA
methylation (Supplementary Figure 7e), while H3K9me3 levels
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were also unchanged (Supplementary Figure 7f). Collectively,
these data show that RELB is a key regulator of the innate
immune response in ECs, which acts in a DNA methylation and
H3K9me3-independent manner to limit ERV expression (Sup-
plementary Figure 7g).
Discussion
This study highlights the importance of PKM2 for growth and
homoeostasis of the vascular endothelium and identifies mole-
cular changes associated with its absence. PKM2 has been linked
with anabolic cell growth in various experimental settings10,11,47,
and its loss is associated with a PKM1-dependent impairment of
pyrimidine synthesis and cell cycle arrest in MEFs25. In the
present study, we observed distinct changes in metabolism in
PKM2KD and PKMKD ECs, indicating that the PKM isoforms
differentially regulate EC metabolism. For example, oxygen
consumption and [U-13C6]-glucose labelling of citrate were
increased only in PKM2KD ECs, indicating that PKM1 may
enhance the oxidative metabolism of glucose in mitochondria. In
contrast, we observed reduced labelling of lactate and α-KG, and
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Fig. 6 Loss of PKM2 impairs methylation capacity, reduces DNA methylation and leads to the expression of endogenous retroviral elements. a Western
blot analysis of MAT2A, P53, P21 and PKM2 in control, P53KD, PKM2KD and PKM2KD/P53KD ECs. b Relative levels of S-adenosylmethionine and S-
adenosylhomocysteine and SAM/SAH ratio in control, P53KD, PKM2KD and PKM2KD/P53KD ECs (n= 3). c Percentage 5-methylcytosine (5mC) levels in
control and PKM2KD ECs (n= 4). d Heat map of protein expression for components of the cellular response to viral infection in control and PKM2KD ECs.
e Representative confocal projections of total double-stranded RNA (dsRNA) staining in control and PKM2KD ECs (scale bar= 20 μm). f Normalized
fluorescence intensity for dsRNA staining in control and PKM2KD ECs (n= 7). g Relative mRNA expression of the indicated endogenous retroviruses in
control and PKM2KD ECs (n= 3). h Restriction digestion of bisulfite-treated DNA amplified from the MLT1B and MER4D genomic loci from control and
PKM2KD ECs (U, undigested/unmethylated DNA; D, digested/methylated DNA). i Relative mRNA expression of the indicated endogenous retroviruses
and interferon-stimulated genes in control, RELBKD, PKM2KD and PKM2KD/RELBKD ECs. b, c, f, g, i Data represent means ± s.d. (***P < 0.001, **P < 0.01, *P
< 0.05 by one-way analysis of variance (ANOVA) followed by Tukey’s HSD test)
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PKMKD ECs, indicating that the levels of these metabolites are
predominantly regulated by PKM2. Recent genetic analyses in
mouse have demonstrated that chronic deletion of PKM2 does
not impact cell proliferation, due to compensatory upregulation
of the Pkm splice isoform PKM114,48. Our genetic analysis of
PKM2 function, using conditional deletion of PKM2 specifically
in ECs, reveals that loss of PKM2 reduces EC proliferation in vivo
and indicates that acute loss or transient inhibition of PKM2 may
lead to fundamentally different effects on cell growth than
chronic loss. Furthermore, we provide evidence that impaired
nucleotide synthesis in cells lacking PKM2 can be regulated at the
transcriptional level by RELB-P53 signalling. The NF-κB and P53
transcriptional networks are known to respond to a variety of
cellular stress stimuli, and our data indicate that RELB-P53 sig-
nalling may play an important role in the response of the
endothelium to metabolic dysfunction, by limiting cell growth.
There is an increasing appreciation of the important link
between intermediary metabolism and chromatin structure and
function32,49, with the availability of nutrients linked to mod-
ifications of DNA50 and histones51. One of the most striking
metabolic changes that we observed in ECs lacking PKM2 was a
reduction in the one-carbon metabolite, SAM, which is required
for the methylation of a broad range of substrates, including
cytosine residues in DNA. In yeast, the PKM2 orthologue Pyk1
was identified as a component of a complex named SESAME
(serine-responsive SAM containing metabolic enzyme complex),
that was shown to regulate chromatin modifications52. While in
the present study we did not identify an orthologous mammalian
SESAME complex, we observed protein-level changes in a
number of key enzymes in the serine, glycine and one-carbon
metabolic network. Decreased expression of the SAM-
synthesizing enzyme MAT2A and reduced steady-state levels of
SAM were independent of P53, indicating that this effect is not
merely a consequence of cell cycle arrest. Taken together, these
data indicate that loss or inhibition of PKM2 may lead to changes
in chromatin structure and function.
As a consequence of DNA hypomethylation, we observed
increased ERV, dsRNA and ISG levels in ECs lacking PKM2. The
fold induction of ERV and ISG expression in PKM2KD ECs was
more limited than previously reported in HCT116 cells treated
with DNMT inhibitors40. These differences may reflect the rela-
tively minor changes in DNA methylation observed in PKM2KD
ECs, or result from cell-type-specific differences in ERV de-
repression, as previously described53. Examination of published
microarray analyses of Pkm2 knockout MEFs25 shows increased
expression of a number of ISGs, indicating that loss of PKM2 can
trigger innate immune signalling in different cell types. In addi-
tion to its role in the maintenance of metabolic homoeostasis,
global deletion of Pkm2 was recently shown to result in systemic
inflammation in mice14. Our data indicate that inflammation
associated with loss of PKM2 may, at least in part, be due to the
de-repression of endogenous retroviral elements that trigger
chronic activation of autoimmune signalling in both ECs and
other cell types. More broadly, they indicate that metabolic dys-
function may be a trigger for autoimmune disease. The role of
NF-κB in the regulation of immune signalling is well estab-
lished54. We have uncovered a homoeostatic function for RELB as
a suppressor of ERV expression in ECs, which limits activation of
antiviral innate immune signalling. The mechanisms through
which RELB limits ERV expression remain to be identified, and
could involve modifications to local chromatin composition or
direct regulation of transcription (Supplementary Figure 7g).
Examination of previously published microarray analysis of bone
marrow dendritic cells from Relb−/− mice45 shows that RELB
limits ISG expression, likely by limiting ERV expression, in
multiple cell types. Furthermore, Relb knockout mice display
chronic inflammation characterized by immune cell infiltration
into multiple tissues55, a phenotype we hypothesize may occur as
a result of ERV de-repression. Collectively, these findings broaden
our understanding of how endothelial metabolism is controlled
and link metabolic changes with the control of growth, epige-
netics and immune responses in ECs.
Methods
Cell culture. Human umbilical vein endothelial cells (HUVECs) were purchased
from Lonza or Life Technologies, authenticated for EC marker expression and
cultured until the fourth passage. HUVECs were cultured in endothelial basal
medium-2 (EBM-2, Lonza) supplemented with foetal bovine serum, hydro-
cortisone, human basic fibroblast growth factor, vascular endothelial growth factor,
R3-insulin-like growth factor, ascorbic acid, human epidermal growth factor, GA-
1000 and heparin. Human embryonic kidney (HEK) cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal calf
serum (Thermo), 100 units/ml penicillin and 100 μg/ml streptomycin. Both cell
lines were cultured in 5% CO2 at 37 °C.
RNA interference. For pan-PKM or PKM2-specific silencing, siRNAs directed
against PKM or specifically targeting exon 10 of the PKM gene have been described
previously20. We validated the effect of three siRNA duplexes by assessing
knockdown efficiency using RT-qPCR and western blot, and cell proliferation by
quantifying EdU+ cell numbers, glucose uptake, lactate and ATP levels. The fol-
lowing siRNA duplex was used for further studies: PKM2_si156:ccauaaucguccu-
caccaa. P53, RELA, RELB and REL were targeted with pools of siRNA duplexes
(Mission esiRNA, Sigma). A negative control pool of four siRNAs (ON-TAR-
GETplus Non-targeting pool, Dharmacon) was used to control for transfection.
Transfections were performed using Lipofectamine RNAiMAX (Invitrogen) with
the manufacturer's standard protocol. For all RNAi experiments, cells were re-
seeded 24 h after siRNA transfection to reach a confluence of ~80% at 48 h after
transfection.
RT-qPCR. RNA was isolated using the miRNeasy micro Kit (Qiagen) combined
with on-column DNase digestion (DNase-Free DNase Set, Qiagen). An aliquot of
1 μg of RNA was used for reverse transcription with the Maxima First Strand
cDNA Synthesis Kit (Thermo). All PCR reactions were run on a CFX Connect




CTTATCCTCATGATTACCGCAG. For analysis of endogenous retrovirus
expression, previously published primer pairs were used40. Expression levels were
normalized to Tbp expression and fold changes calculated using the ΔΔCt method.
Western blot analysis and antibodies. HUVECs were lysed in modified RIPA
buffer (150 mM NaCl, 50 mM Tris–HCl pH 7.4, 1% IGEPAL, 0.1% sodium deox-
ycholate, 1 mM EDTA) supplemented with protease inhibitors (cOmplete ULTRA
Mini, Roche) and PMSF. Proteins were separated using SDS-PAGE on precast
TGX gradient gels (Biorad) and then transferred to polyvinylidine fluoride mem-
branes using the Transblot Turbo Transfer System (Bio-Rad). Membranes were
blocked in 5% BSA for 1 h, probed with primary antibodies overnight at 4 °C and
then with peroxidase-conjugated secondary antibodies. The following antibodies
were used: PKM1 (Cell Signaling Technology, #7067, 1:1000), PKM2 (Cell Sig-
naling Technology, #4053, 1:1000), P21 (Cell Signaling Technology, #2947, 1:1000),
P53 (Cell Signaling Technology, #9282, 1:500), P53 (Santa Cruz, sc-126, 1:1000),
RELB (Cell Signaling Technology, #10544, 1:1000), MAT2A (Novus Biologicals,
#NB110-94158, 1:2000), β-actin (Cell Signaling Technology, #8457, 1:1000),
GAPDH (Cell Signaling Technology, #2118, 1:2000) and anti-rabbit IgG-HRP
(Santa Cruz Biotechnology, sc-2004, 1:10,000). For analysis, membranes were
incubated with ECL (Clarity Western ECL Substrate, Biorad) and imaged using a
ChemiDoc MP system (Biorad). Uncropped images of blots are presented in
Supplementary Figure 8.
Seahorse metabolic analysis. Functional metabolic analyses in HUVECs were
performed using a Seahorse XFe96 analyser (Seahorse Bioscience) according to the
manufacturer’s protocol. In brief, HUVECs (40,000 per well) were seeded on
fibronectin-coated XFe96 microplates. After 2 h, the cell medium was changed to a
non-buffered assay medium and cells were maintained in a non-CO2 incubator for
1 h. Using the Glycolysis Stress Test Kit, extracellular acidification rate (ECAR) was
assessed under basal conditions, and sequentially following the addition of glucose
(10 mM), the mitochondrial ATP synthase inhibitor oligomycin (3 µM) or 2-
deoxy-D-glucose (2-DG; 100 mM), an inhibitor of glycolysis. Using the Mito Stress
Test Kit, oxygen consumption rate (OCR) was measured sequentially under basal
conditions, after injection of oligomycin (3 µM), the mitochondrial uncoupler
carbonyl cyanide-4-(trifluoromethoxy)phenyl-hydrazone (FCCP; 1 µM), and after
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injection of a mix of the respiratory chain inhibitors antimycin A (1.5 µM) and
rotenone (3 µM).
Lactate assay. Lactate concentration was measured in HUVEC cell culture
medium that was conditioned for 12 h. The measurement was performed with a
Lactate assay kit (Biovision) following the manufacturer’s protocol.
Glucose uptake assay. Endothelial glucose uptake was assessed by analysing the
uptake of 2-NBDG (2-(N-(7-Nitobenz-2oxa-1,3-diazol-4-yl)Amino)-2-Deox-
yglucose) (Life Technologies), a fluorescent glucose analogue. HUVECs were
incubated for 1 h in media containing 100 µM 2-NBDG and fluorescence was
measured using the BD FACS LSR II flow cytometer. Data were analysed with the
BD FACSDiva software (Version 8.0.1).
Immunostaining of cell cultures. Twenty-four hours after transfection, HUVECs
were re-seeded in 96-well imaging plates (Ibidi) to reach ~80% confluence at 48 h
after transfection. For EdU staining, cells were cultured in EGM2 media containing
10 μM EdU (Thermo) for 3 h prior to fixation at 37 °C and in 5% CO2. Cells were
fixed in 4% PFA for 15 min at room temperature and then permeabilised with 0.5%
Triton X-100 for 15 min. To prevent antibody binding to non-specific epitopes,
blocking was performed for 1 h in 5% goat serum, 1% BSA and 0.1% Triton X-100.
Primary antibodies were diluted in blocking solution and incubated overnight at 4 °
C. The following primary antibodies were used: phospho-Histone H3 (Cell Sig-
naling Technology, #9713, 1:500) and J2A (Scicons, 1:200). Alexa Fluor-conjugated
secondary antibodies were used for detection (Thermo, 1:250). The Click-iT EdU
Alexa Fluor 647 imaging kit was used for detection of EdU incorporation
(Thermo). Imaging was performed using an LSM800 Observer (Zeiss).
Cell cycle analyses. Control, PKM2KD, PKMKD, P53KD and/or PKM2KD/P53KD
HUVECs were harvested 48 h after transfection at ~80% confluence. Adherent cells
were fixed in ice-cold 70% ethanol and then stored at −20 °C overnight. For
staining, cells were washed twice in PBS, resuspended in a solution of 50 mg/ml
propidium iodide (Sigma-Aldrich) containing RNase (Sigma-Aldrich #R6513) in
0.1% Triton X-100 and incubated for 20 min at 37 °C. Data were acquired using a
BD FACS LSR II flow cytometer.
In vitro scratch wound assay. HUVECs were transfected with contol or
PKM2 siRNAs and after 24 h seeded in 24-well plates to reach 100% confluency at
48 h after transfection. At this stage, a scratch wound was applied to the EC
monolayer using a 200 μl pipette tip, and individual wells were imaged (T0).
HUVECs were incubated for a further 8 h in complete media, photographed again
and the percentage wound closure in ctrl and PKM2KD ECs calculated using
ImageJ.
Generation of zebrafish mutants with TALENs and CRISPR/Cas9. Animals
were maintained under standard conditions and all experiments were conducted in
accordance with institutional (MPG) and national ethical and animal welfare
guidelines. TALENs were used to generate pkma2s717 mutants and CRISPR/Cas9
was used to generate pkmbs718 mutants as previously described56. For the gen-
eration of pkma2 mutants, TALEN arms composed of the following RVDs tar-
geting exon 10 of the pkma gene were used: NN NI HD HD HD NN NG NN NI
HD HD HD NG NG HD NI NN NI NG NN HD and NG NG NN NI NI NN NN
NI NI NN HD HD NG HD NN NI HD NN NN. RNA was synthesized with
mMESSAGE mMachine (Ambion) and 50 pg per TALEN arm was injected into
one-cell stage embryos to generate potential founders (F0). Analysis of mRNA
expression in pkma2+/+ and pkma2−/− embryos at 26 hpf revealed no changes in
pkma1 expression in pkma2 mutants (Supplementary Figure 2h). For CRISPR/
Cas9, sgRNAs were designed using the CRISPR Design online toolbox (http://
crispr.mit.edu) and the following guide sequence was used to target exon 5 of the
pkmb gene: TGTGGAACAGGGCGTGGACATGG. Guide RNAs were made by
ligating annealed primers into the pT7-gRNA vector, and the pT3Ts-nCas9n
plasmid (Addgene) was used to synthesize Cas9 mRNA. To generate founders,
between 50 pg of sgRNA and 250 pg of Cas9 mRNA were coinjected into one-cell
stage embryos. F0 founders for each gene were identified by outcrossing TALEN or
CRISPR/Cas9-injected fish with AB and screening the offspring at 24 hpf using
HRMA. PCR products from F0 founders that showed promising HRMA melt
curves were cloned and sequenced, and those with frameshift mutations were
grown. Primer sequences for HRMA genotyping were as follows: pkma2_HR-
MA_fwd: CTGTTCTGACCCGTGACCCTTC; pkma2_HRMA_rev: GGTGAG
TATGATGATGCCGC; pkmb_HRMA_fwd: CTGAGAAGGACATCAAGGACC;
pkmb_HRMA_rev: AGCAGCTTTGCGGATAAAGGAGG. Mutants were gener-
ated in the Tg(kdrl:EGFP)s843 background57.
Mouse experiments. Animals were maintained under standard conditions and all
experiments were conducted in accordance with institutional (MPG) and national
ethical and animal welfare guidelines. Conditional PKM2 mutant mice
(Pkmtm1.1Mgvh) were backcrossed to the C57/Bl6 background. For conditional EC-
specific deletion, PKM2-floxed mice were bred with Tg(Pdgfb-icre/ERT2)1Frut mice,
which express the tamoxifen-inducible CreERT2 in ECs. For analysis of angio-
genesis in the retina, postnatal mice were injected intraperitoneally with 25 μl of 4-
Hydoxytamoxifen (2 mg/ml, H6278, Sigma) on postnatal days (P)1–P3 and retinas
were harvested on P7. Control animals were littermates without CreERT2
expression. Due to the nature of the experimental setup, animals were randomly
assigned to treatment groups. Only litters that reached normal body weight at P7
were used. Mice that were more than 1.5 interquartile ranges (IQR) above or below
the upper or lower IQR for their respective litter were not analysed.
Immunostaining and analysis of postnatal retinas. For quantitative analysis of
angiogenesis, eyes were harvested from P7 mice and fixed in 4% PFA on ice for 2 h.
After fixation, eyes were washed in PBS and then dissected to remove the retinal
tissue. Following dissection, retinas were incubated in blocking buffer (3% normal
goat serum, 1% BSA, 0.5% Triton X-100 and 0.5% Tween-20) for 1 h at RT and
then incubated with primary antibodies diluted in incubation buffer (1.5% normal
goat serum, 0.5% BSA, 0.25% Triton X-100 and 0.25% Tween-20) overnight at
4 °C. Primary antibodies against the following proteins were used: PECAM (1:200,
#AF3628, R&D Systems), ERG (1:200, #ab92513, Abcam), Collagen IV (1:400,
#2150-1470, AbD Serotec). After primary antibody incubation, retinas were washed
four times in 0.1% PBS Triton X-100 and incubated with Alexa Fluor-conjugated
secondary antibodies (Thermo, 1:250) for 2 h at RT. Following secondary antibody
staining, retinas were washed four times in 0.1% PBS Triton X-100 and the Click-
iT EdU Alexa Fluor 647 imaging kit was used for detection of EdU incorporation
(Thermo). Retinas were mounted on glass slides using Vectashield (Vector Labs)
and imaging was performed using a Zeiss LSM700 or Leica SP8 microscope. All
images were acquired without prior knowledge of the genotype of the individual
samples.
Quantitative analysis of the retinal vasculature. Outgrowth of the retinal vas-
culature was measured using ImageJ software as the distance from the centre of the
optic nerve to the periphery of the vessel bed in each leaflet of dissected retinas. The
mean distance of individual leaflets was taken as the value for each sample. For
quantification of EC and EdU+ EC number, vessel area, branch point density and
empty Collagen IV sleeves, four fields per sample were acquired using a ×25
objective. The total number of ECs and EdU+ EC number was determined using
Imaris Software. The mean of four fields per sample at the angiogenic front or
central plexus was taken as the value for each sample. EC area per field and branch
point density was determined using the AngioTool software. Empty Collagen IV
sleeves were counted manually using ImageJ. These analyses were not blinded.
LC-HRMS metabolomics and flux analysis. For measurement of steady-state
metabolite levels, control, PKM2KD, PKMKD, P53KD and/or PKM2KD/P53KD
HUVECs were harvested 48 h after transfection in 80% methanol pre-cooled to
−80 °C. Plates were transferred to a −80 °C freezer for 15 min to inactivate enzyme
functions, then scraped into extraction solvent and centrifuged at 20,000 × g for
10 min at 4 °C. The supernatant was then collected and dried for ~2 h in a speed-
vac at room temperature. Dried pellets were stored at −80 °C. For flux analyses,
50:50 labelling was performed using [U-13C6]glucose (Cambridge Isotope
Laboratories, Inc) as a tracer, and metabolite extraction and storage was performed
as above. Metabolomics was performed using liquid chromatography-high reso-
lution mass spectrometry (LC-HRMS). An ultimate 3000 UHPLC (Dionex) is
coupled to the Q Exactive Plus-Mass spectrometer (QE-MS, Thermo Scientific, San
Jose, CA) for metabolite separation and detection. Detailed instrument method
information was described previously58. Samples were reconstituted into 30 µl
sample solvent (water:methanol:acetonitrile, 2:1:1, v/v), and 4 μl was injected to the
LC-QE-MS. The peak area of each metabolite was used to present relative abun-
dance and to calculate the isotopologue distribution. All data are provided in
Supplementary Data File 1.
Proteomics analysis. Control and PKM2KD HUVECs were harvested in 4% SDS,
0.1 M Tris–HCl (pH 7.6) 48 h after transfection. Samples were sonicated, clarified
by centrifugation and protein concentration was estimated using the DCA protein
assay kit. Proteins were separated using SDS-PAGE on precast TGX gradient gels
(Bio-Rad) and stained using the Colloidal Blue staining kit (Invitrogen). Each lane
of the gel was cut into slices, and proteins were digested as previously described56.
Briefly, gel pieces were washed with 50 mM ammoniumbicarbonate and ethanol,
reduced with 10 mM DTT for 45 min at 56 °C, carbamidomethylated with 55 mM
iodoacetamide for 30 min at RT in the dark, and then digested with trypsin
overnight. The next day, peptides were extracted from the gel pieces using
increasing concentrations of acetonitrile. Samples were cleaned up with Stage Tips
(Stop and go extraction) and then measured with LC-MS/MS on a QExactive HF.
Separation of peptides according to their hydrophobicities was achieved on a 15 cm
in-house packed column (internal diameter 75 μm, C18 Beads (Dr. Maisch) dia-
meter 1.8 μm) using a binary buffer system: (A) 0.1% formic acid in H2O and (B)
0.1% formic acid in 80% acetonitrile. The following gradient of 75 min was used:
5 min 10% of B, 50 min 38% of B, 5 min 60% of B, 10 min 95% of B, 5 min 5% of B.
Mass spectra were acquired at a resolution of 60,000 (200m/z) using an AGC target
of 3e6 and a maximal injection time of 20 ms. A top 15 method was applied for
subsequent acquisition of high-energy collision-induced dissociation (HCD)
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fragmentation MS/MS spectra of the 15 most intense peaks. Fragmentation (MS/
MS) was performed with a resolution of 15,000 at 2.2m/z and and AGC target of
1e5 within a maximal injection time of 25 ms. Raw files were processed using
MaxQuant 1.5.5.1 and the Andromeda search engine. For peptide assignment, MS/
MS HCD fragmentation spectra were correlated to the Uniprot Homo sapiens
database (2016). Further downstream analyses were performed as previously
described. All data are provided in Supplementary Data File 2.
RNA-seq analysis and data processing. RNA was isolated from 48 h after
transfection from control, P53KD, PKM2KD and PKM2KD/P53KD HUVECs using
the miRNeasy micro Kit (Qiagen) combined with on-column DNase digestion
(DNase-Free DNase Set, Qiagen). RNA and library preparation integrity were
verified with a BioAnalyzer 2100 (Agilent) or LabChip Gx Touch 24 (Perkin
Elmer).2 µg of total RNA was used as input for Truseq Stranded mRNA Library
preparation following the low sample protocol (Illumina). Sequencing was per-
formed on the NextSeq500 instrument (Illumina) using v2 chemistry, resulting in a
minimum of 37M reads per library with 1 × 75 bp single end setup. The resulting
raw reads were assessed for quality, adaptor content and duplication rates with
FastQC59. Reaper version 13–100 was employed to trim reads after a quality drop
below a mean of Q20 in a window of ten nucleotides60. Only reads between 30 and
150 nucleotides were cleared for further analyses. Trimmed and filtered reads were
aligned to the GRCh37.p5 human genome assembly using STAR 2.4.0a with the
parameter “--outFilterMismatchNoverLmax 0.1” to increase the maximum ratio of
mismatches to mapped length to 10%61. The number of reads aligning to genes was
counted with the featureCounts 1.4.5-p1 tool from the Subread package62. Only
reads mapping at least partially inside exons were admitted and aggregated per gene.
Reads overlapping multiple genes or aligning to multiple regions were excluded.
Differentially expressed genes were identified using DESeq2 version 1.6263.
5-methylcytosine quantification. The levels of 5-methylcytosine were measured
using the MethylFlash Methylated DNA quantification kit (Epigenetik) according
to the instructions of the manufacturer.
Chromatin immunoprecipitation (ChIP). ChIP was performed using the truChIP
Chromatin Shearing Reagent kit (Covaris) according to the manufacturer’s
instructions. Chromatin was sheared (Bioruptor, Diagenode) to generate fragments
between 200 and 400 bp. 5 μg of DNA was used for each immunoprecipitation and
10% was stored as an input. Immunoprecipitation was performed following a
published protocol64 using the following antibodies: Mouse IgG (2 μg/IP, 5441S,
Cell Signaling) and Histone H3 (tri methyl K9) (2 μg/IP, ab8898, Abcam). Fol-
lowing immunoprecipitation and reverse cross-linking, samples and inputs were
purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel) fol-
lowing the manufacturer’s instructions for samples containing SDS.
Bisulfite conversion and restriction analyses. Genomic DNA was isolated from
80% confluent control, PKM2KD, P53KD, PKM2KD/P53KD, RELBKD and PKM2KD/
RELBKD HUVECs 48 h after transfection, using the DNeasy Blood & Tissue kit
(Qiagen, 69504). Bisulfite conversion was performed using the EpiJET Bisulfite
Conversion Kit (Thermo Scientific, #K1461) according to the manufacturer’s
instructions. PCR amplification of bisulfite-converted DNA was performed using




D_Rev—CCTCTAACACTACCTTAACTCAAACATTTC. Following PCR ampli-
fication, samples were purified and then digested with HpyCH4III (MER4D) or
HincII (MLT1B) for 8 h, and visualized on a 3% agarose gel.
Blinding. The individual genotypes of mice and zebrafish were unknown before
data analysis was performed.
Statistical analyses. No statistical tests were used to predetermine sample size.
Statistical analyses were performed by unpaired, two-tailed Student's t test, or non-
parametric one-way ANOVA followed by Tukeys HSD test using GraphPad Prism
software. Data are represented as mean ± s.d. for individual data points and mean
± s.e.m. where values presented are calculated as a mean of means. P values <0.05
were considered significant. All metabolomic (Figs. 1c–l, 4b, 5f, 6b, and Supple-
mentary Figures 1e–j, 5f–g, 6a), transcriptomic (Figs. 4c, 6d and Supplementary
Figures 4a, e, 5a, 6b), proteomic (Fig. 5e and Supplementary Figures 5b, 6c, 7b),
RT-qPCR (Figs. 1a, 6g, i and Supplementary Figures 1c, 7b), ChIP RT-qPCR
(Supplementary Figure 7a, f) and phenotypic (Figs. 2a–c, 5a, c and Supplementary
Figures 1a-c, 5c, d) analyses were performed by transfecting primary HUVECs
pooled from multiple donors (n= number of independent transfections). For
in vivo analyses in zebrafish (Fig. 2d, e) and mouse (Fig. 3b, d and Supplementary
Figure 3e), n= number of independent animals observed. Sample sizes were
selected on the basis of published protocols65.
Data availability
RNA-seq data are deposited in the Gene Expression Omnibus under accession number
GSE84877. Metabolomics (Supplementary Data File 1) and proteomics (Supplementary
Data File 2) data are provided as supplementary data files.
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